SCHEMBL2951087

SCHEMBL2951087

CCCOCCOCCC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR3 O14843 1/20 0.50
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
AKR1B1 P15121 1/20 0.44
GPR84 Q9NQS5 7/20 0.42
PPARG P37231 7/20 0.42
PPARD Q03181 7/20 0.42
PPARA Q07869 7/20 0.42
HDAC11 Q96DB2 5/20 0.42
TSHR P16473 4/20 0.42
PTPN1 P18031 3/20 0.42
ALDH1A1 P00352 3/20 0.42
TLR2 O60603 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
FABP4 P15090 2/20 0.42
HSD17B10 Q99714 2/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
SLC22A8 Q8TCC7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2721342 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL26900519 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL18738574 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL25576277 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL2948540 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL15158837 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL16420210 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL2949542 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL22445018 1.00 FFAR3 (0.50) FFAR3HDAC3HDAC1HDAC2HDAC8
SCHEMBL260630 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466912-B2 Blocked polyisocyanate composition, heat-curable resin composition, cured product, and production method therefor KOEI CHEMICAL COMPANY, LIMITED (JP) 2025-11-11 US disclosed
US-20250215117-A1 METHOD FOR PRODUCING ESTERIFIED POLYSACCHARIDE KOEI CHEMICAL COMPANY, LIMITED (JP) 2025-07-03 US disclosed
EP-4578879-A1 METHOD FOR PRODUCING ESTERIFIED POLYSACCHARIDE Koei Chemical Company, Limited (JP) 2025-07-02 EP disclosed
US-12291506-B2 Method for producing amidate compound, and amidate compound KOEI CHEMICAL COMPANY, LIMITED (JP) 2025-05-06 US disclosed
US-20250122323-A1 ONIUM SALT, BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANTE COMPOSITION INCLUDING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, AND CURED PRODUCT AND MANUFACTURING METHOD THEREFOR KOEI CHEMICAL COMPANY, LIMITED (JP) 2025-04-17 US disclosed
US-20250109090-A1 METHOD FOR PRODUCING ONIUM SALT AND METHOD FOR PURIFYING ONIUM SALT KOEI CHEMICAL COMPANY, LIMITED (JP) 2025-04-03 US disclosed
EP-4530284-A1 METHOD FOR PRODUCING ONIUM SALT AND METHOD FOR PURIFYING ONIUM SALT Koei Chemical Company, Limited (JP) 2025-04-02 EP disclosed
CN-119707822-A Method for producing onium salt and method for purifying onium salt 广荣化学株式会社 2025-03-28 CN disclosed
CN-115052864-B Method for producing carboxylate compound and method for producing amidate compound 广荣化学株式会社 2025-02-28 CN disclosed
CN-118290346-A Method for producing amide compound, and amide compound 广荣化学株式会社 2024-07-05 CN disclosed
US-20170014528-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS INVICTUS ONCOLOGY PVT. LTD. (IN) 2017-01-19 US disclosed
US-20160317623-A1 MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF THE SCRIPPS RESEARCH INSTITUTE 2016-11-03 US disclosed
EP-1886759-B1 WATER-SOLUBLE PREFLUX AND USE THEREOF SHIKOKU CHEM (JP) 2016-10-05 EP disclosed
US-20160009669-A1 ONIUM SALT, LIQUID COMPOSITION CONTAINING SAID ONIUM SALT AND CELLULOSE, AND CELLULOSE RECOVERY METHOD KOEI CHEMICAL COMPANY, LIMITED (JP) 2016-01-14 US disclosed
US-20150111759-A1 METHOD OF PREPARATION OF NANOPORE AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-04-23 US disclosed
US-20130224227-A1 NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS BYONDIS B.V. (NL) 2013-08-29 US disclosed
WO-2011133039-A2 NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS SYNTARGA B.V. (NL) 2011-10-27 WO disclosed
US-7754105-B2 Water-soluble preflux and usage of the same SHIKOKU CHEMICALS CORPORATION (JP) 2010-07-13 US disclosed
US-20080318070-A1 Water-Soluble Preflux and Usage of the Same SHIKOKU CHEMICALS CORPORATION (JP) 2008-12-25 US disclosed
EP-1886759-A1 WATER-SOLUBLE PREFLUX AND USE THEREOF SHIKOKU CHEMICALS CORPORATION (JP) 2008-02-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009669-A1 ONIUM SALT, LIQUID COMPOSITION CONTAINING SAID ONIUM SALT AND CELLULOSE, AND CELLULOSE RECOVERY METHOD CEL, CROCC, ALG1 FFAR3 3525/4885HDAC3 1342/4885HDAC1 1045/4885
US-20170014528-A1 TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS ABCG2, ADAM8, TIE1 FFAR3 3888/4885HDAC3 1855/4885HDAC1 1779/4885
US-20160317623-A1 MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF SGMS1, SGMS2, PHOSPHO1 FFAR3 3082/4885HDAC3 2423/4885HDAC1 1443/4885
US-12291506-B2 Method for producing amidate compound, and amidate compound NAAA, NIT2, PAM FFAR3 634/4885HDAC3 604/4885HDAC1 1250/4885
US-20250109090-A1 METHOD FOR PRODUCING ONIUM SALT AND METHOD FOR PURIFYING ONIUM SALT NOTUM, CA7, CROCC FFAR3 955/4885HDAC3 675/4885HDAC1 345/4885
US-12466912-B2 Blocked polyisocyanate composition, heat-curable resin composition, cured product, and production method therefor THEM6, PUF60, PSMC6 FFAR3 111/4885HDAC3 1054/4885HDAC1 725/4885
US-20250122323-A1 ONIUM SALT, BLOCKING AGENT DISSOCIATION CATALYST FOR BLOCKED ISOCYANATE, BLOCKED ISOCYANTE COMPOSITION INCLUDING BLOCKING AGENT DISSOCIATION CATALYST, THERMOSETTING RESIN COMPOSITION, AND CURED PRODUCT AND MANUFACTURING METHOD THEREFOR KDM2B, O60361, IDH3B FFAR3 1327/4885HDAC3 1153/4885HDAC1 48/4885
US-20130224227-A1 NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS PCNA, DCLRE1A, CDC5L FFAR3 3946/4885HDAC3 2457/4885HDAC1 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.